In conclusion, we established a dual target, light-controlled delivery strategy for monoclonal antibodies with EGFR-targeting immune liposomes, light-controlled release from endosomes and light-mediated inactivation of Ki-67 as molecular switch to provoke efficient tumor cell elimination. This evidence concerns the gene MKI67 and neoplasm.